Floatz logo

Eloxatin

Indolent B-cell Non-Hodgkin Lymphoma (iNHL)

Reid Merryman, MDPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Indolent B-cell Non-Hodgkin Lymphoma (iNHL) cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
Genmab
Phase 1/2CCC
Epcoritamab
Genmab
Phase 1/2CCC

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →